当前位置: X-MOL 学术Clin. Gastroenterol. Hepatol. › 论文详情
Predicting, Preventing, and Managing Treatment-related Complications in Patients With Inflammatory Bowel Diseases.
Clinical Gastroenterology and Hepatology ( IF 7.958 ) Pub Date : 2020-02-11 , DOI: 10.1016/j.cgh.2020.02.009
Laurent Beaugerie,Jean-François Rahier,Julien Kirchgesner

Risk of complications from specific classes of drugs for inflammatory bowel diseases (IBD) can be kept low by respecting contra-indications. Patients with IBD frequently develop serious infections, due to the disease itself or its treatment. At the time of diagnosis, patients' vaccination calendars should be updated according to IBD guidelines-live vaccines should be postponed for patients receiving immunosuppressive drugs. Opportunistic infections should be detected and the vaccine against Pneumococcus should be given before patients begin immunosuppressive therapy. Thiopurines promote serious viral infections, in particular, whereas tumor necrosis factor (TNF) antagonists promote all types of serious and opportunistic infections. Severe forms of varicella can be prevented by vaccinating seronegative patients against varicella zoster virus. Detection and treatment of latent tuberculosis is mandatory before starting anti-TNF therapy and other new IBD drugs. Tofacitinib promotes herpes zoster infection in a dose- and age-dependent manner. Physicians should consider giving patients live vaccines against herpes zoster before they begin immunosuppressive therapy or a recombinant vaccine, when available, at any time point during treatment. Risk of thiopurine-induced lymphomas can be lowered by limiting the use of thiopurines in patients who are seronegative for Epstein-Barr virus (especially young men) and in older men. The risk of lymphoma related to monotherapy with anti-TNF agents is still unclear. There are no robust data on carcinogenic effects of recently developed IBD drugs. For patients with previous cancer at substantial risk of recurrence, physicians should try to implement a pause in the use of immunosuppressive therapy (except in patients with severe disease and no therapeutic alternative) and prioritize use of IBD drugs with lowest carcinogenic effects. Finally, sun protection and skin surveillance from the time of diagnosis are recommended.
更新日期:2020-02-12

 

全部期刊列表>>
向世界展示您的会议墙报和演示文稿
全球疫情及响应:BMC Medicine专题征稿
欢迎探索2019年最具下载量的化学论文
新版X-MOL期刊搜索和高级搜索功能介绍
化学材料学全球高引用
ACS材料视界
x-mol收录
自然科研论文编辑服务
南方科技大学
南方科技大学
西湖大学
中国科学院长春应化所于聪-4-8
复旦大学
课题组网站
X-MOL
深圳大学二维材料实验室张晗
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug